In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.
about
Isavuconazole in the treatment of invasive aspergillosis and mucormycosis infectionsEmerging drugs and vaccines for candidemiaAdvances in the treatment of invasive neonatal candidiasisIsavuconazole for the treatment of invasive aspergillosis and mucormycosis: current evidence, safety, efficacy, and clinical recommendationsIsavuconazole: A New Broad-Spectrum Triazole Antifungal AgentMucormycosis caused by unusual mucormycetes, non-Rhizopus, -Mucor, and -Lichtheimia speciesIn vitro antifungal activity of isavuconazole against Madurella mycetomatisApophysomyces elegans: epidemiology, amplified fragment length polymorphism typing, and in vitro antifungal susceptibility patternAntifungal agents for the treatment of systemic fungal infections in children.Isavuconazole: A New Option for the Management of Invasive Fungal Infections.Isavuconazole: a new and promising antifungal triazole for the treatment of invasive fungal infections.A phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared with fluconazole in patients with uncomplicated esophageal candidiasisSafety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation studyPharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection modelSpecific antifungal susceptibility profiles of opportunists in the Fusarium fujikuroi complex.The challenge of managing fusariosisIn Vitro Activity of Isavuconazole and Comparators against Clinical Isolates of the Mucorales OrderSpecial considerations for the diagnosis and treatment of invasive pulmonary aspergillosis.Activity of Isavuconazole and Other Azoles against Candida Clinical Isolates and Yeast Model Systems with Known Azole Resistance Mechanisms.Evaluation of Etest method for determining isavuconazole MICs against Cryptococcus gattii and Cryptococcus neoformans.In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds.Fusarium infection in lung transplant patients: report of 6 cases and review of the literature.Isavuconazole Population Pharmacokinetic Analysis Using Nonparametric Estimation in Patients with Invasive Fungal Disease (Results from the VITAL Study)Population Pharmacokinetics of Isavuconazole from Phase 1 and Phase 3 (SECURE) Trials in Adults and Target Attainment in Patients with Invasive Infections Due to Aspergillus and Other Filamentous Fungi.Isavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model.In vitro susceptibility of Aspergillus fumigatus to isavuconazole: correlation with itraconazole, voriconazole, and posaconazole.Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei.Isavuconazole (BAL4815) pharmacodynamic target determination in an in vivo murine model of invasive pulmonary aspergillosis against wild-type and cyp51 mutant isolates of Aspergillus fumigatus.Fusarium Osteomyelitis in a Patient With Pearson Syndrome: Case Report and Review of the Literature.New and investigational triazole agents for the treatment of invasive fungal infections.Effect of mild and moderate liver disease on the pharmacokinetics of isavuconazole after intravenous and oral administration of a single dose of the prodrug BAL8557.New generation azole antifungals in clinical investigation.New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance.In vitro susceptibility testing in Aspergillus species: an update.Detection and investigation of invasive mould disease.Addressing current medical needs in invasive fungal infection prevention and treatment with new antifungal agents, strategies and formulations.Candida peritonitis: an update on the latest research and treatments.Invasive aspergillosis: resistance to antifungal drugs.Profile of isavuconazole and its potential in the treatment of severe invasive fungal infectionsIsavuconazole, a broad-spectrum triazole for the treatment of systemic fungal diseases.
P2860
Q26744049-183637D4-AD4C-4456-9D80-750DCA99C5B3Q26828993-5F369D89-EF71-4794-BC8C-46C31A0333AEQ27022585-EDC139CC-C031-4087-B7AF-18B13F16E075Q28067726-EFBA26A7-FF77-4DAE-877B-B80091B750C1Q28082019-27DFD39F-D97D-436A-8936-0BE7F4468C99Q28389719-9B529CBD-E2E8-466D-AAF6-0F4CAC4884C3Q34298778-0481444B-1E83-463F-A1A1-8B5F4A5C42F0Q34433129-86C622DC-69D5-4DF1-9EF2-C48E50A82A02Q34437094-34113322-3B34-43DC-BDB4-C86D386BF7C3Q34474946-6EDAB950-D21B-4DD6-A54D-DCF5277C9E1EQ34900399-35F03BCE-1296-41CA-9945-A15212CC5C34Q35076974-9A1CBC74-38A3-44BA-8398-26C16855DABEQ35168889-4BB51ED0-E3D5-4075-91D1-4C5295710DF7Q35385554-BC169B3B-E233-4F22-8690-D72F444775FAQ35533576-3B095B65-7854-4413-9A27-582C08D951E1Q35693680-78638693-FC6B-4FCC-A6B9-19DA065F3941Q36290764-755775DA-EBBC-4C4D-B4AC-E6C6AAAF50D7Q36396166-F5BD2727-D4DC-4FFF-8E10-168BFE096448Q36439061-5A9339E2-0CF4-4942-9062-F88B7CB8325FQ36804054-A87A3ECE-B154-4F36-8F4B-4FC2C8D02266Q37036173-5348DF63-D0C7-419A-A01B-569E054E455FQ37114436-DAB4F7D2-3260-4D1A-B4F8-EB8076BCA3BAQ37119937-0372751F-EADF-4D93-9A3F-D6C7CE8C2F98Q37203893-F8A88062-9CC3-456F-A3F8-59CB1041F2A5Q37263435-5F11F9DC-3DFD-438A-A889-9AA4A8EF97E9Q37263445-EF186EFC-D062-4D97-AA97-3B5BA802726DQ37291463-CC777EDC-E09F-42F5-9F57-35F23C0996E8Q37335649-D407E75A-B535-4A26-8542-FB7B807AA92BQ37343483-3975D5E6-F086-4E29-8CB8-927ED0B1F9DDQ37364295-4DCD046A-3DBC-4933-98DE-9C5575161639Q37409882-5CD86624-C8DC-4DAE-AE1E-00C9812E724FQ37579222-A5DEE86C-6883-4FBF-8044-6BF9C3BCCF9AQ37608276-A3A5958F-5734-4E09-B7D6-A0882A45DE97Q37742178-32A2D4CC-0984-405F-824F-63D93241E8CFQ37823011-ABC7B0D5-4721-4895-BB5A-9384EDB9D972Q37918556-AEB40701-E823-4786-A263-1A1D9A4167B7Q37942794-D70061C5-09BD-4DAD-81F7-3A8841E84FCAQ37983464-275AEC5C-12AD-4497-A0D2-FB51CF0F8886Q38159688-AC237709-F44F-41DD-81B6-620A1896A74AQ38285488-B10CDFC3-2C2D-4BDF-BD66-77BAC93B2B76
P2860
In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
In vitro antifungal activities ...... ium, and Scedosporium species.
@en
In vitro antifungal activities ...... ium, and Scedosporium species.
@nl
type
label
In vitro antifungal activities ...... ium, and Scedosporium species.
@en
In vitro antifungal activities ...... ium, and Scedosporium species.
@nl
prefLabel
In vitro antifungal activities ...... ium, and Scedosporium species.
@en
In vitro antifungal activities ...... ium, and Scedosporium species.
@nl
P2093
P2860
P356
P1476
In vitro antifungal activities ...... ium, and Scedosporium species.
@en
P2093
Jesús Guinea
Marta Torres-Narbona
Sandra Recio
Teresa Peláez
P2860
P304
P356
10.1128/AAC.01512-07
P407
P50
P577
2008-01-22T00:00:00Z